AKT1 and myeloid sarcoma: Cognitive impairment is known to be involved in the mTOR signaling pathway [56,57], PI3K/Akt/mTOR signaling pathway [58], cholesterol biosynthesis pathway [59,60], cholinergic pathway [61,62,63], visual pathway [64], etc. Management of cognitive dysfunction and decline in MS patients is more important to improve the lifestyle of people with MS.